Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Balchem (BCPC) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Balchem (BCPC) over the last 15 years, with Q3 2025 value amounting to -$10000.0.

  • Balchem's Asset Writedowns and Impairment rose 8245.61% to -$10000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$57000.0, marking a year-over-year decrease of 12080.29%. This contributed to the annual value of $299000.0 for FY2024, which is 70810.81% up from last year.
  • According to the latest figures from Q3 2025, Balchem's Asset Writedowns and Impairment is -$10000.0, which was up 8245.61% from -$29000.0 recorded in Q2 2025.
  • In the past 5 years, Balchem's Asset Writedowns and Impairment registered a high of $328000.0 during Q1 2022, and its lowest value of -$132000.0 during Q3 2023.
  • Its 5-year average for Asset Writedowns and Impairment is $42052.6, with a median of $36000.0 in 2023.
  • In the last 5 years, Balchem's Asset Writedowns and Impairment plummeted by 1310000.0% in 2023 and then surged by 61935.48% in 2024.
  • Over the past 5 years, Balchem's Asset Writedowns and Impairment (Quarter) stood at $75000.0 in 2021, then tumbled by 70.67% to $22000.0 in 2022, then skyrocketed by 63.64% to $36000.0 in 2023, then soared by 69.44% to $61000.0 in 2024, then crashed by 116.39% to -$10000.0 in 2025.
  • Its Asset Writedowns and Impairment was -$10000.0 in Q3 2025, compared to -$29000.0 in Q2 2025 and -$79000.0 in Q1 2025.